SCHEMBL3759744

SCHEMBL3759744

CNc1cn[c]c(-c2ccccc2)c1N1CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 2/20 0.36
ALDH1A1 P00352 6/20 0.36
NPC1 O15118 5/20 0.36
RAB9A P51151 4/20 0.36
HPGD P15428 5/20 0.34
HSD17B10 Q99714 4/20 0.34
KDM4E B2RXH2 4/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MAPT P10636 3/20 0.34
TP53 P04637 2/20 0.34
TSHR P16473 2/20 0.34
AR P10275 1/20 0.34
RECQL P46063 1/20 0.34
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34
MAT2A P31153 2/20 0.34
LMNA P02545 4/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
TDP1 Q9NUW8 3/20 0.33
HTT P42858 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759709 0.96 NPY5R (0.32) NPY5RALDH1A1NPC1RAB9AHPGD
SCHEMBL3757772 0.79 HSD17B10 (0.40) ALDH1A1NPC1RAB9AHPGDHSD17B10
SCHEMBL3760258 0.77 HTT (0.38) ALDH1A1NPC1RAB9AHPGDHSD17B10
SCHEMBL3763874 0.76 KMT2A (0.44) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL3751655 0.74 KMT2A (0.45) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL3763028 0.74 LMNA (0.35) ALDH1A1NPC1RAB9AHPGDHSD17B10
SCHEMBL3754790 0.73 NPY5R (0.43) NPY5RALDH1A1NPC1RAB9AHPGD
SCHEMBL3757720 0.73 TDO2 (0.34) ALDH1A1HPGDHSD17B10KDM4EMAPT
SCHEMBL3760546 0.72 LRRK2 (0.37) NPY5RALDH1A1NPC1RAB9AHPGD
SCHEMBL3760043 0.72 SMN1; SMN2 (0.44) NPC1RAB9AHPGDSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA NPY5R 4725/4885ALDH1A1 3061/4885NPC1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.